Literature DB >> 11170132

Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression.

S C Xi1, S W Siu, S W Fong, S Y Shiu.   

Abstract

BACKGROUND: Potential involvement of the mt1 receptor in the antiproliferative action of melatonin on androgen-sensitive LNCaP cells, and melatonin-induced modulation of androgen-insensitive PC-3 cell growth, have been reported in vitro. The effects of melatonin on prostate cancer cell proliferation and their association with mt1 receptor expression were investigated in athymic nude mice xenograft models of LNCaP and PC-3 cells.
METHODS: Daily saline or melatonin (4 microg/g body weight) was given to nude mice before or after tumor cell inoculation. Tumor volume was measured periodically, and expression of PCNA, cyclin A, PSA, and mt1 receptor was assessed by immunohisto(cyto)chemistry and/or Western blotting.
RESULTS: Melatonin inhibited the growth of LNCaP tumors, without affecting the growth of PC-3 xenografts, in nude mice. It induced significant decreases in the expression of PCNA, cyclin A, and PSA in LNCaP tumors. Expression of mt1 receptor protein was demonstrated in LNCaP cells, but not in PC-3 cells, both in vivo and in vitro.
CONCLUSIONS: The antiproliferative action of melatonin on LNCaP tumor growth was demonstrated in vivo, and its association with mt1 receptor protein expression suggests the potential involvement of the receptor in the antitumor activity of the pineal gland hormone. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170132     DOI: 10.1002/1097-0045(200101)46:1<52::aid-pros1008>3.0.co;2-z

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  21 in total

Review 1.  Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies.

Authors:  Lara G Sigurdardottir; Unnur A Valdimarsdottir; Katja Fall; Jennifer R Rider; Steven W Lockley; Eva Schernhammer; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254

2.  Sleep disruption among older men and risk of prostate cancer.

Authors:  Lara G Sigurdardottir; Unnur A Valdimarsdottir; Lorelei A Mucci; Katja Fall; Jennifer R Rider; Eva Schernhammer; Charles A Czeisler; Lenore Launer; Tamara Harris; Meir J Stampfer; Vilmundur Gudnason; Steven W Lockley
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05       Impact factor: 4.254

Review 3.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

4.  Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells.

Authors:  Konrad Kleszczyński; Tae-Kang Kim; Bernadetta Bilska; Michal Sarna; Krystian Mokrzynski; Agatha Stegemann; Elżbieta Pyza; Russel J Reiter; Kerstin Steinbrink; Markus Böhm; Andrzej T Slominski
Journal:  J Pineal Res       Date:  2019-10-07       Impact factor: 13.007

Review 5.  Functional MT1 and MT2 melatonin receptors in mammals.

Authors:  Margarita L Dubocovich; Magdalena Markowska
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

6.  Melatonin Induces Apoptotic Cell Death via p53 in LNCaP Cells.

Authors:  Chi Hyun Kim; Yeong-Min Yoo
Journal:  Korean J Physiol Pharmacol       Date:  2010-12-31       Impact factor: 2.016

7.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 8.  WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.

Authors:  Zsofia Kiss; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2016-09-22       Impact factor: 5.678

9.  Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of Ras.

Authors:  Scot R Kimball; Ahmed Abbas; Leonard S Jefferson
Journal:  J Pineal Res       Date:  2008-05       Impact factor: 13.007

10.  Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival.

Authors:  Gabriela Oprea-Ilies; Erhard Haus; Linda Sackett-Lundeen; Yuan Liu; Lauren McLendon; Robert Busch; Amy Adams; Cynthia Cohen
Journal:  Breast Cancer Res Treat       Date:  2012-12-19       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.